Wanner, Christoph

EMPA-REG OUTCOME: The Nephrologist's Point of View

Wanner, C. (2017) · The American Journal of Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 57

Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial

Reifsnider, O. S., Kansal, A. R., Wanner, C., Pfarr, E., Koitka-Weber, A., Brand, S. B., Stargardter, M., Wang, C., Kuti, E., & Ustyugova, A. (2022) · American Journal of Kidney Diseases

Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management

Cited by 52

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial

Fitchett, D., Inzucchi, S. E., Wanner, C., Mattheus, M., George, J. T., Vedin, O., Zinman, B., & Johansen, O. E. (2020) · European Heart Journal

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 34

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 12